OSCR trades 14.8% above Wall Street's consensus target of $24.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OSCR achieves its forward estimates and maintains a stable P/E multiple of 31.5x. This scenario reflects the blended consensus of 11 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 20, 2026, Oscar Health, Inc. (OSCR) has a Wall Street consensus price target of $24.20, based on estimates from 11 covering analysts. With the stock currently trading at $28.40, this represents a potential downside of -14.8%. The company has a market capitalization of $7.36B.
Analyst price targets range from a low of $16.00 to a high of $35.00, representing a 79% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, OSCR trades at a trailing P/E of -16.8x and forward P/E of 31.5x. Analysts expect EPS to grow +853.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CLOVClover Health Investments, Corp. | $2.6B | $5.00 | $4.47 | -10.6% | Hold | 129.2x | 9 |
ALHCAlignment Healthcare, Inc. | $4.5B | $21.86 | $24.33 | +11.3% | Buy | 118.7x | 16 |
ACGLArch Capital Group Ltd. | $32.5B | $91.18 | $102.57 | +12.5% | Buy | 9.8x | 34 |
BHVNBiohaven Ltd. | $1.4B | $13.57 | $17.60 | +29.7% | Buy | — | 25 |
MIRAMIRA Pharmaceuticals, Inc. | $40M | $0.95 | — | — | — | — | — |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
CVSCVS Health Corporation | $125.4B | $98.32 | $103.64 | +5.4% | Buy | 13.3x | 41 |
CICigna Corporation | $73.6B | $279.27 | $340.91 | +22.1% | Buy | 9.2x | 39 |
ELVElevance Health Inc. | $84.4B | $388.50 | $415.19 | +6.9% | Buy | 14.5x | 37 |
CNCCentene Corporation | $30.1B | $61.02 | $59.00 | -3.3% | Buy | 17.5x | 43 |
Quick answers to the most common questions about buying OSCR stock.
OSCR's consensus price target is $24.2, -14.8% below the current price of $28.4. The 11 analysts tracking OSCR see downside risk at present valuations.
OSCR has a consensus rating of "Hold" based on 11 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $24.2 implies -14.8% downside from current levels.
OSCR trades at a forward P/E of 31.517x, representing a moderate valuation. With analysts targeting $24.2 (-14.8% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $35 for OSCR, while the most conservative target is $16. The consensus of $24.2 represents the median expectation. These targets typically reflect 12-month expectations.
OSCR is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OSCR stock forecast based on 11 Wall Street analysts shows a consensus price target of $24.2, with estimates ranging from $16 (bear case) to $35 (bull case). The median consensus rating is "Hold".
OSCR trades at a forward P/E ratio of 31.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on OSCR, with 2 Sell ratings and a price target of $24.2 (-14.8% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OSCR analyst price targets range from $16 to $35, a 79% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24.2 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.